Open AccessEffect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease
Author(s) -
John L. Lyles,
Aditi Mulgund,
Laura Bauman,
Weiji Su,
Fang Lin,
Deepika L. Chona,
Puneet Sharma,
Renee K Etter,
Jennifer Hellmann,
Lee A. Denson,
Phillip Minar,
Dana M. H. Dykes,
Michael J. Rosen
Publication year - 2020
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izaa102
Subject(s) - medicine , therapeutic drug monitoring , odds ratio , vedolizumab , hazard ratio , inflammatory bowel disease , retrospective cohort study , guideline , confidence interval , disease , pharmacokinetics , pathology
Reports on the feasibility and effectiveness of translating proactive, antitumor necrosis factor (TNF) therapeutic drug monitoring (TDM) for inflammatory bowel disease into practice-wide quality improvement (QI) are lacking. We aimed to determine whether a TDM QI program improved outcomes at a large academic pediatric gastroenterology practice.